<div><div></div><div><span><p><span>Rhythm Pharmaceuticals' Chief Financial Officer, Smith Hunter C, sold a total of 6,628 shares of common stock on February 4th and 5th, 2026, under a Rule 10b5-1 plan adopted on February 28, 2025. The transactions were executed at weighted average prices ranging from $104.34 to $108.08, resulting in a total sale amount of $702,744. Following these transactions, Smith Hunter C directly owns 125,537 shares of the company.</span></p><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Smith Hunter C</span></td></tr><tr><td><span>Relationship</span></td><td><span>Chief Financial Officer</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$702,744</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>SEC Filing: </span>RHYTHM PHARMACEUTICALS, INC. [ RYTM ] - Form 4 - Feb. 06, 2026</p><section><b><span class="heading-aHOVUrmQ">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

RYTM

SBIO

<p>Rhythm Pharmaceuticals' CFO, Smith Hunter C, sold 6,628 shares of common stock on February 4th and 5th, 2026, under a Rule 10b5-1 plan. The shares were sold at prices between $104.34 and $108.08, totaling $702,744. After the sale, he retains ownership of 125,537 shares. The transaction was reported in SEC Form 4.</p>

TradingView

Rhythm Pharma

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

VG Health

iShares Global Healthcare

iShares Biotechnology ETF

Health Care Select Sector SPDR

Rhythm Pharmaceuticals CFO Sells Shares